Format

Send to

Choose Destination
Curr Urol Rep. 2019 Sep 3;20(10):64. doi: 10.1007/s11934-019-0931-3.

Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.

Author information

1
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
2
Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA. rkpachynski@wustl.edu.
3
Center for Human Immunology and Immunotherapy Programs (CHiiPs), Washington University School of Medicine, St. Louis, MO, USA. rkpachynski@wustl.edu.
4
Siteman Cancer Center, Washington University in St. Louis, 660 S. Euclid Ave., Campus Box 8056, St. Louis, MO, 63110, USA. rkpachynski@wustl.edu.

Abstract

PURPOSE OF REVIEW:

To date, prostate cancer has been poorly responsive to immunotherapy. In the current review, we summarize and discuss the current literature on the use of vaccine therapy and checkpoint inhibitor immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).

RECENT FINDINGS:

Sipuleucel-T currently remains the only FDA-approved immunotherapeutic agent for prostate cancer. Single-agent phase 3 vaccine trials with GVAX and PROSTVAC have failed to demonstrate survival benefit to date. Clinical trials using combination approaches, including combination PROSTVAC along with a neoantigen vaccine and checkpoint inhibitor immunotherapy, are ongoing. Checkpoint inhibitor monotherapy clinical trials have demonstrated limited efficacy in advanced prostate cancer, and combination approaches and molecular patient selection are currently under investigation. The optimal use of vaccine therapy and checkpoint inhibitor immunotherapy in metastatic castration-resistant prostate cancer remains to be determined. Ongoing clinical trials will continue to inform future clinical practice.

KEYWORDS:

Castration resistance; Checkpoint inhibitors; Immunotherapy; Metastatic prostate cancer; Neoantigen vaccine; Vaccines

PMID:
31482315
DOI:
10.1007/s11934-019-0931-3

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center